Literature DB >> 6170378

Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin.

B Hughes, B R Madan, J R Parratt.   

Abstract

1 The intravenous administration of E. coli endotoxin (2 mg/kg) in cats anaesthetized with pentobarbitone resulted in an initial acute increase in right atrial pressure and a transient systemic hypotension. Later (from 1 h onwards) there was a progressive decrease in cardiac output, a reduced right atrial filling pressure, systemic hypotension and a profound metabolic acidosis (lactate of 30 +/- 1 mg/100 ml at 5 h compared with 5.1 +/- 0.5 mg/100 ml pre-endotoxin). Only one of eight animals so treated survived 8 h. 2 Polymyxin B sulphate, given intravenously (1 min before endotoxin) as a bolus injection (5 mg/kg) followed by a continuous intravenous infusion (additional 5 mg/kg given over a 30 min period) prevented the endotoxin-induced pulmonary (right atrial) hypertension but not the acute systemic hypotension. 3 Polymyxin B sulphate reduced the delayed haemodynamic effects of endotoxin (systemic hypotension, decrease in cardiac output); all the eight animals so treated survived 8 h compared with only 1/8 of the controls. 4 Polymyxin B did not prevent the initial (1-3 h) and marked metabolic acidosis following endotoxin; however, after 3 h, arterial lactate levels returned towards control whereas in the endotoxin-alone group they continued to increase until death. 5 The mechanism of this marked protective effect of the antibiotic and the possible clinical repercussions are discussed; the most likely explanation for the protection is in chemical combination with the lipid A moiety of the endotoxin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170378      PMCID: PMC2071766          DOI: 10.1111/j.1476-5381.1981.tb10481.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Further studies on the antipyretic action of polymyxin B in pyrogen-induced fever.

Authors:  A S van Miert; C T van Duin
Journal:  Arzneimittelforschung       Date:  1978

2.  Effect of methylprednisolone and polymyxin B sulfate on endotoxin-induced inhibition of human neutrophil chemotaxis.

Authors:  A C Issekutz; W D Biggar
Journal:  J Lab Clin Med       Date:  1978-12

3.  Chemical and electrophoretic changes induced by polymyxin B on outer membrane components from Serratia marcescens.

Authors:  D A Brown; J C Tsang
Journal:  J Antibiot (Tokyo)       Date:  1978-06       Impact factor: 2.649

4.  Neutralization of the hemodynamic effects of endotoxin by polymyxin B.

Authors:  J D Palmer; D Rifkind
Journal:  Surg Gynecol Obstet       Date:  1974-05

5.  Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate.

Authors:  J J Corrigan; B M Bell
Journal:  J Lab Clin Med       Date:  1971-05

6.  Electron microscopy of effect of polymyxin on Escherichia coli lipopolysaccharide.

Authors:  J Lopes; W E Inniss
Journal:  J Bacteriol       Date:  1969-11       Impact factor: 3.490

7.  Myocardial and circulatory effects of E. coli endotoxin; modification of responses to catecholamines.

Authors:  J R Parratt
Journal:  Br J Pharmacol       Date:  1973-01       Impact factor: 8.739

8.  Prevention by polymyxin B of endotoxin lethality in mice.

Authors:  D Rifkind
Journal:  J Bacteriol       Date:  1967-04       Impact factor: 3.490

9.  Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs.

Authors:  A H From; J S Fong; R A Good
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

10.  The value of polymixin B in endotoxaemia due to experimental obstructive jaundice and mesenteric ischaemia.

Authors:  C J Ingoldby
Journal:  Br J Surg       Date:  1980-08       Impact factor: 6.939

View more
  9 in total

1.  The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats.

Authors:  B Hughes; J R Parratt
Journal:  Br J Pharmacol       Date:  1985-10       Impact factor: 8.739

2.  A national survey of screening for congenital dislocation of the hip.

Authors:  C Dezateux; S Godward
Journal:  Arch Dis Child       Date:  1996-05       Impact factor: 3.791

3.  Dose-response relationship for the antipyretic effect of meloxicam in an endotoxin model in cats.

Authors:  C Justus; J F Quirke
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

Review 4.  Clinical relevance of antibiotic-induced endotoxin release.

Authors:  J M Prins; S J van Deventer; E J Kuijper; P Speelman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide.

Authors:  R L Danner; K A Joiner; M Rubin; W H Patterson; N Johnson; K M Ayers; J E Parrillo
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  In vivo and in vitro studies of bacterial endotoxin-membrane interactions and the effects of membrane-active agents.

Authors:  M E Garnett; D V Godin; J M Tuchek
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

7.  Plasma acid phosphatase levels in endotoxaemia: modification by drugs and chemically detoxified endotoxins.

Authors:  D V Godin; J M Tuchek
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

8.  Resveratrol, a natural antioxidant, has a protective effect on liver injury induced by inorganic arsenic exposure.

Authors:  Zhigang Zhang; Li Gao; Yanyan Cheng; Jing Jiang; Yan Chen; Huijie Jiang; Hongxiang Yu; Anshan Shan; Baojing Cheng
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

9.  Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Authors:  Yaakov Dickstein; Leonard Leibovici; Dafna Yahav; Noa Eliakim-Raz; George L Daikos; Anna Skiada; Anastasia Antoniadou; Yehuda Carmeli; Amir Nutman; Inbar Levi; Amos Adler; Emanuele Durante-Mangoni; Roberto Andini; Giusi Cavezza; Johan W Mouton; Rixt A Wijma; Ursula Theuretzbacher; Lena E Friberg; Anders N Kristoffersson; Oren Zusman; Fidi Koppel; Yael Dishon Benattar; Sergey Altunin; Mical Paul
Journal:  BMJ Open       Date:  2016-04-20       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.